Literature DB >> 11768771

Mechanisms and clinical implications of renal drug excretion.

R Masereeuw1, F G Russel.   

Abstract

The body defends itself against potentially harmful compounds like drugs, toxic compounds, and their metabolites by elimination, in which the kidney plays an important role. Renal clearance is used to determine renal elimination mechanisms of a drug, which is the result of glomerular filtration, active tubular secretion and reabsorption. The renal proximal tubule is the primary site of carrier-mediated transport from blood to urine. Renal secretory mechanisms exists for, anionic compounds and organic cations. Both systems comprises several transport proteins, and knowledge of the molecular identity of these transporters and their substrate specificity has increased considerably in the past decade. Due to overlapping specificities of the transport proteins, drug interactions at the level of tubular secretion is an event that may occur in clinical situation. This review describes the different processes that determine renal drug handling, the techniques that have been developed to attain more insight in the various aspects of drug excretion, the functional characteristics of the individual transport proteins, and finally the implications of drug interactions in a clinical perspective.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768771     DOI: 10.1081/dmr-120000654

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  21 in total

1.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

2.  Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria.

Authors:  Jens Rengelshausen; Jürgen Burhenne; Margit Fröhlich; Yorki Tayrouz; Shio Kumar Singh; Klaus-Dieter Riedel; Olaf Müller; Torsten Hoppe-Tichy; Walter E Haefeli; Gerd Mikus; Ingeborg Walter-Sack
Journal:  Eur J Clin Pharmacol       Date:  2004-10-13       Impact factor: 2.953

Review 3.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

Review 4.  A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation.

Authors:  Hélène M Faessel; R Scott Obach; Hans Rollema; Patanjali Ravva; Kathryn E Williams; Aaron H Burstein
Journal:  Clin Pharmacokinet       Date:  2010-12       Impact factor: 6.447

Review 5.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

6.  Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.

Authors:  Max Taubert; Joseph Chiesa; Mark Lückermann; Carsten Fischer; Axel Dalhoff; Uwe Fuhr
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

7.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

8.  Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation.

Authors:  Jia Yin; Haichuan Duan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-10-06       Impact factor: 4.030

9.  Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity.

Authors:  Li Xia; Mingyan Zhou; Thomas F Kalhorn; Horace T B Ho; Joanne Wang
Journal:  Am J Physiol Renal Physiol       Date:  2009-04-08

10.  A quantitative threshold for high/low extent of urinary excretion of compounds in humans.

Authors:  Rutwij A Dave; Marilyn E Morris
Journal:  Biopharm Drug Dispos       Date:  2016-07       Impact factor: 1.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.